Baxter to buy hemodialysis giant Gambro AB for $4 billion

Share this article:
Baxter to buy hemodialysis giant Gambro AB for $4 billion
Baxter to buy hemodialysis giant Gambro AB for $4 billion

After almost a year of negotiations, Baxter has reached a $4 billion deal for Swedish firm Gambro AB.

The acquisition is part of a larger effort by Baxter to corner the kidney dialysis market. Gambro AB is one of the largest makers of hemodialysis (HD) equipment. HD is the most widely used form of treatment for patients with advanced kidney failure in hospitals or treatment centers.

Baxter's renal products generate $629 million in revenue—a third of the company's $1.9 billion medical products business, according to their Q3 earnings statement. Baxter's renal portfolio currently consists of peritoneal dialysis (PD) equipment. PD differs from HD in that it allows patients to give themselves treatments at home and on-the-go. Its flexibility aside, PD remains the less common of the two and is restrictive in terms of drug interactions and diet.

According to the NIH in 2009, nearly 400,000 end-stage renal disease (or ESRD) patients were being treated by some form of dialysis. Of those, “more than 10 times as many ESRD patients receive hemodialysis treatment at a clinic as those who do peritoneal dialysis and home HD combined,” said NIH.

Sweden's Carnegie investment bank analyst Kristofer Liljeberg said this buy gives Baxter the second seat behind Fresenius in the clinical dialysis market. During a Baxter call to discuss the acquisition with analysts, Liljeberg noted, “I think in the longer term, the ambition is to try and challenge Fresenius,” as reported by Reuters.

In its most recent earnings statement, Fresenius Medical Care cited total dialysis product revenue at $1.2 billion. Through its international network of 3,135 dialysis clinics, Fresenius provides dialysis treatment for 256,251 patients. They plan to continue growth in 2013 by opening new clinics and acquiring existing ones.

The deal is expected to close sometime in the first half of 2013. Baxter expects the purchase to reduce earnings per share through 2013 and to add modest gains by 2014. They estimate sales will increase by 7-8% over the next five years.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...